Advances in anti-BRAF therapies for lung cancer

Giandomenico Roviello, Alberto D'Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

Research output: Contribution to journalReview articlepeer-review

19 Citations (SciVal)


Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.

Original languageEnglish
Pages (from-to)879-890
Number of pages12
JournalInvestigational New Drugs
Issue number3
Early online date21 Jan 2021
Publication statusPublished - 30 Jun 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).


  • BRAF
  • Lung cancer
  • V600

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Advances in anti-BRAF therapies for lung cancer'. Together they form a unique fingerprint.

Cite this